As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-291699 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Beyond Air, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 47-3812456 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

As filed with the U.S. Securities and Exchange Commission on December 11, 2025. Registration No. 333-[•] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––– FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––– Brand Meditech Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) | Cayman Islands | 5047 | Not Applicable | | --- | --- | --- | | (State or other jurisd ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues and health risks associated with the altered G7 devices were downplayed by the defendants [3]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - The public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [3]. - Shareholders are encouraged to register for the class action by December 26, 2025, to be eligible for potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant awareness of the issues [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to October 29, 2025, with a deadline for shareholders to register by December 15, 2025 [3][4]. - Shareholders who purchased shares during the class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had actually fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Performance - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Inspire Medical Systems, Inc. is facing allegations of misleading investors regarding the launch of its new product, Inspire V, which reportedly failed due to poor demand and inadequate preparations [3][4]. Group 1: Allegations and Issues - The class period for the allegations is from August 6, 2024, to August 4, 2025 [3]. - The complaint states that the launch of Inspire V was a disaster, with significant surplus inventory and reluctance from providers to transition to the new treatment [3]. - Defendants allegedly made false statements about the successful launch, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [3][4]. Group 2: Shareholder Actions - Shareholders who purchased INSP shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline of January 5, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that led to artificial inflation of the company's stock [5].

KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025. Financial Highlights Generated revenue of $22.6 million in Q2 FY26, an increase of 53% compared to the prior year period.Expanded gross margin to 50.6% in Q2 FY26 compared to 39.6% in the prior year period.Increased FY26 revenue guidance to $91 million, ...

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about the operational readiness of its new device, Inspire V, leading to significant financial losses for investors [1][2]. Summary by Relevant Sections Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for full commercial rollout, which concealed critical operational failures [2][4]. - The lawsuit highlights that the necessary software updates for Medicare claims processing did not take effect until July 1, 2025, delaying the rollout and revenue generation [3]. - There was a significant surplus of the older Inspire IV device, which impacted demand for the new Inspire V product, leading to a drastic cut in 2025 EPS guidance by over 80% [3]. Financial Impact - The stock price of Inspire Medical dropped by $42.04 per share, representing a 32.4% decline in value following the revelation of these operational issues [3]. - The lawsuit claims that many treatment centers had not completed the essential training and onboarding required to implant the new device, further complicating the launch [3]. Legal Actions and Investor Rights - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, including the Medicare claims software failure and the inventory glut of the prior device [4].

NEW YORK--(BUSINESS WIRE)---- $ITGR #BFA--Integer Holdings Corporation Lowered Sales Outlook Triggers Securities Fraud Class Action after Stock Drops Over 32% -- Investors Urged to Contact BFA. ...

Core Insights - Intuitive Surgical (ISRG) has received FDA clearance to expand the use of the da Vinci Single Port (SP) robotic system for inguinal hernia repair, cholecystectomy, and appendectomy surgeries, significantly broadening its application in general surgery [1][8] - The single-port methods are expected to support less invasive surgeries, resulting in reduced trauma, faster recovery, lower costs, and improved patient experience [2][10] - The da Vinci SP system's enhancements and the rise in minimally invasive cases contributed to a 91% growth in SP procedures in Q3 [8][11] Company Performance - Following the FDA announcement, ISRG's shares declined by 0.4%, but year-to-date, the shares have increased by 6.5%, outperforming the industry growth of 3.2% and the S&P 500's rise of 19.5% [3] - ISRG currently has a market capitalization of $200.08 billion [5] Competitive Position - The FDA clearance positions ISRG to enhance its competitive edge in minimally invasive surgery by linking its technology to three common surgical procedures in the U.S., potentially increasing demand for its single-port robots [4] - The ongoing evolution of the da Vinci SP system aims to improve patient care and support the company's long-term growth in minimally invasive surgery [10][11]